Sheri Volger

Janssen (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index1.8kcitations71works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(20), Obesity and Health Practices(12), Obesity, Physical Activity, Diet(11), Immunodeficiency and Autoimmune Disorders(10), Microscopic Colitis(9)

Publications71 total

41: USTEKINUMAB OPEN-LABEL INDUCTION AND RANDOMIZED BLINDED MAINTENANCE THERAPY IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: THE PHASE 3 UNITI JR STUDY
Gastroenterology·2025
P1123 Baseline characteristics and nutrition in patients with moderately to severely active Inflammatory Bowel Disease: Results from the phase 3 UNITI Jr and UNIFI Jr trials
Journal of Crohn s and Colitis·2025
Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results
Journal of Pediatric Gastroenterology and Nutrition·2024· 10 citedOpen Access
Mo2040 COMPARISON OF PEDIATRIC PATIENTS AND YOUNG ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
Gastroenterology·2024
Mo2049 THE EFFECT OF USTEKINUMAB ON MUCOSAL INFLAMMATION IN PEDIATRIC CROHN'S DISEASE: THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
Gastroenterology·2024
Mo2037 USTEKINUMAB IN DEVELOP: A SAFETY ANALYSIS FROM AN INFLAMMATORY BOWEL DISEASE MULTICENTER, PROSPECTIVE, LONG-TERM REGISTRY OF PEDIATRIC PATIENTS
Gastroenterology·2024
Mo2039 COMPARISON OF ALL PEDIATRIC PATIENTS AND YOUNG ADULTS WITH CROHN'S DISEASE TREATED WITH USTEKINUMAB IN THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
Gastroenterology·2024Open Access
Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease
Journal of Crohn s and Colitis·2024· 1 citedOpen Access
P1063 Comparison of all paediatric patients and young adults with Crohn’s Disease treated with ustekinumab in the REALITI Real-World Evidence Effectiveness Study
Journal of Crohn s and Colitis·2024Open Access
P864 The Effect of Ustekinumab on Mucosal Inflammation in Paediatric Crohn’s Disease: The REALITI Real-World Evidence Effectiveness Study
Journal of Crohn s and Colitis·2024Open Access
P958 Comparison of Paediatric Patients and Young Adults with Moderately to Severely Active Crohn’s Disease Treated with Ustekinumab in the REALITI Real-World Evidence Effectiveness Study
Journal of Crohn s and Colitis·2024Open Access
P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients
Journal of Crohn s and Colitis·2024Open Access
Tu2009 USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE UNISTAR STUDY LONG-TERM EXTENSION
Gastroenterology·2023
Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel disease
Journal of Comparative Effectiveness Research·2023· 2 citedOpen Access
P671 Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension
Journal of Crohn s and Colitis·2023· 3 citedOpen Access
Validating the Simplified Endoscopic Mucosal Assessment for Crohn’s Disease: A Novel Method for Assessing Disease Activity
Inflammatory Bowel Diseases·2022· 12 citedOpen Access
VALIDATION OF THE SIMPLIFIED ENDOSCOPIC MUCOSAL ASSESSMENT OF CROHN’S DISEASE (SEMA-CD) A NOVEL ENDPOINT TO ASSESS ENDOSCOPIC IMPROVEMENT WITH REAL WORLD DATA
Inflammatory Bowel Diseases·2022Open Access
VALIDATION OF THE SIMPLIFIED ENDOSCOPIC MUCOSAL ASSESSMENT OF CROHN’S DISEASE (SEMA-CD) A NOVEL ENDPOINT TO ASSESS ENDOSCOPIC IMPROVEMENT WITH REAL WORLD DATA
Gastroenterology·2022Open Access
Sugar-sweetened beverage purchases and intake at event arenas with and without a portion size cap
Preventive Medicine Reports·2021· 3 citedOpen Access
Sa581 FEASIBILITY OF USING REAL-WORLD DATA FROM THE IMPROVECARENOW REGISTRY TO EXAMINE THE EFFICACY OF USTEKINUMAB FOR PEDIATRIC CROHN'S DISEASE
Gastroenterology·2021
page 1 of 4Next →

Frequent Co-authors

David B. Sarwer(14), Thomas A. Wadden(13), Marion Vetter(10), Reneé H. Moore(8), Adam Gilden Tsai(6), Stanley A. Cohen(6), Jesse Chittams(5), Eva Panigrahi(5), Ilia Tikhonov(5), Robert I. Berkowitz(4), Lisa K. Diewald(4), M Vetter(4), Jeffrey A. Lavenberg(4), Pamela Rothpletz‐Puglia(4), Laurie S. Conklin(4), Jeffrey S. Hyams(4), Christopher D. O’Brien(3), Colleen Marano(3), J L Perez(3), Livia Dainelli(3)